As is often the case with cancer treatments, many patients are able to benefit from therapy for a time. Tumor activity ...

Targeted Oncology: For the community oncologist, the choice between niraparib and olaparib often comes down to the patient's molecular profile. In a pMMR/HRD-negative patient, what clinical markers ...

Olaparib is the only PARP inhibitor that significantly improves overall survival in PSROC, distinguishing it from other PARP inhibitors. All four PARP inhibitors enhance progression-free survival, ...

PARP inhibitors revolutionize ovarian cancer treatment, offering targeted therapy options and improved outcomes for patients with specific genetic markers. Niraparib approved for all-comers whose ...

Stenoparib is being evaluated in combination with temozolomide clinical benefit in relapsed Small Cell Lung CancerTrial is fully funded by ...

A new study published by Mayo Clinic researchers suggests that ovarian cancer cells quickly activate a survival response ...

In an interview with Targeted Oncology, Erin Crane, MD, MPH, discusses PARP inhibitor restrictions in gynecologic oncology. Watch part 1 of the interview here.

Fallopian tube cancer, a rare gynecologic cancer, is gaining awareness due to its potential origin for many high-grade serous ovarian cancers. New diagnostics improve early detection and treatment, ...

Personalized Medicine. 2015;12(2):139-154. Compared to AstraZeneca, the other pharmaceutical companies have fewer Phase III trials running for their compounds. However, the approaches within these ...

Among patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 alterations, nearly half (48.8%) did not receive a PARP inhibitor, despite recent FDA approvals and recent trials ...

The use of PARP inhibitors for the treatment of patients with BRCA1/2 mutations represents a milestone in genomically-directed therapies. Olaparib and talazoparib have shown to significantly extend ...